Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Coronavirus Scare:...

    Coronavirus Scare: Minister apprises parliament about the availability of drugs and shortages

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-14T15:03:27+05:30  |  Updated On 14 March 2020 9:33 AM GMT
    Coronavirus Scare: Minister apprises parliament about the availability of drugs and shortages

    Delhi: Through a written reply in the Rajya Sabha Shri. D.V. Sadananda Gowda, Minister for Chemicals & fertilizers informed the parliament that enough API's and formulations stock is available in the country. The minister clearly stated that till now there has been no shortage of API and formulations reported

    "National Pharmaceutical Pricing Authority (NPPA) has informed that they have not received any reference regarding the shortage of Active Pharmaceutical Ingredients. The Indian Drugs Manufacturers Association (IDMA) has assured that its members have enough stocks of APIs and formulations," the minister stated

    NPPA has also informed that they have not received any reference from pharma associations regarding the steep increase in the price of medicines due to outbreak of COVID-19 in China. The AIOCD AWACS has reported an increase in drug prices for the month ending February 2020 at 0.6 %. Further, NPPA has issued D.O dated 20.02.2020 to Chief Secretaries of all the States /UTs to monitor the production and availability of APIs and their formulations to prevent black marketing and hoarding and to ensure price compliance as per the Drugs (Prices Control) Order (DPCO,2013) under intimation to NPPA. NPPA has also written to Pharma Associations in the matter. NPPA is monitoring the situation regularly to ensure that the ceiling prices of essential medicines are not breached.

    Read also: Ensure That There Is No Hoarding, Blackmarketing Of Medicines: NPPA Chief Tells States On Covid-19 Outbreak

    Further, Department of Pharmaceuticals has constituted a Committee under the chairmanship of Dr Eshwara Reddy, Joint Drugs Controller, Central Drugs Standard Control Organization (CDSCO) to address the issue of drug security in the country in the context of novel coronavirus outbreak in China. Based on the recommendations of the Committee, the department has issued necessary instructions to National Pharmaceutical Pricing Authority (NPPA) and Drugs Controller General of India (DCGI) to ensure an adequate supply of APIs and formulations at affordable prices in the market and to prevent black-marketing, illegal hoarding, creating artificial shortages in the country. In this regard, the Department of Pharmaceuticals has written to DGFT to restrict exports of 13 API and formulations made using these APIs.

    Read also: Following SC Orders, CDSCO Asks Pharma Manfacturers Submit Data On 66 Fixed-Dose Combinations

    The Indian Pharmaceutical industry is 3rd largest in the world in terms of volume and 14th largest in terms of value. India exported medicines worth US $14389 mn in Financial Year 2018-19. India also exported Bulk Drug/Drug Intermediates worth the US $ 3911mn in Financial Year 2018-19. However, the country also imports various Bulk Drugs/Active Pharmaceutical Ingredients (APIs) for producing medicines. Two-thirds of the total imports of Bulk Drugs/Drug Intermediates is from China. The imports from China are mainly due to economic considerations. The details of India's imports of Bulk Drugs/Drug Intermediates (including from China) are as under:

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    Year

    Total Imports

    (US $ mn)

    Imports from China

    (US$ mn)

    Per cent of Imports from China

    2018-19

    3560.35

    2405.42

    67.56%

    The policies formulated by the Government from time to time are designed to minimize the country's dependence on imports and to give a fillip to indigenous manufacturing. In this direction, the Department of Pharmaceuticals has formulated a Scheme namely 'Assistance to Bulk Drug Industry for Common Facility Centre' for providing assistance to Bulk Drug Industry for Common Facility Centre in any upcoming bulk drug park promoted by State Governments/State Corporations.

    Read also: NPPA gives a deadline to manufacturers to submit availability data of 58 APIs

    coronavirus covid-19 national-pharmaceutical-pricing-authority active-pharmaceutical-ingredients api nppa black-marketing dv-sadananda-gowda 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X